Overview

Granzyme B PET Imaging Drug as a Predictor of Immunotherapy Response in Melanoma or NSCLC Participants

Status:
Recruiting
Trial end date:
2022-02-28
Target enrollment:
Participant gender:
Summary
First in Human Safety of [68Ga]-NOTA-hGZP PET Imaging in Subjects with Melanoma or NSCLC
Phase:
Phase 1
Details
Lead Sponsor:
Cytosite Biopharma Inc.
Collaborators:
Chang Gung Memorial Hospital
Massachusetts General Hospital
University of Alabama at Birmingham